UK Medical Cannabis Market Dominated by Ten Doctors Amid Rapid Private Prescribing Growth and Oversight Challenges

Newly released prescribing figures point to an extraordinary concentration in the UK’s medical cannabis market: ten doctors have issued roughly half of all private prescriptions for cannabis-based medicines. The pattern is not illegal, but it is unusual for a controlled-drug category and exposes structural gaps in governance, data visibility and clinical capacity seven years after cannabis-based products for medicinal use were rescheduled in the UK.

Prescribing is booming – and clustered

Medical cannabis prescribing has expanded rapidly in private clinics while remaining minimal on the National Health Service, where use is largely confined to a narrow set of indications and specialist centres. Regulators have documented sharp year‑on‑year growth in privately dispensed items and warned that oversight must keep pace with the market’s scale and complexity.

These dynamics create a feedback loop: limited NHS participation pushes demand to a handful of private specialists, which in turn concentrates prescribing volume, commercial influence and clinical experience among a small number of clinicians. For policymakers, that concentration sharpens questions about who effectively sets prescribing norms in a field still regarded as experimental in much of the health service.

Why a tiny cohort dominates

• Eligibility rules: Initial prescriptions are restricted to doctors on the General Medical Council’s Specialist Register with relevant expertise, narrowing the pool of initiators and reinforcing reliance on sub‑specialist clinics.
• Guideline conservatism: Evidence thresholds for routine NHS use remain high, especially for chronic pain, where benefits must be weighed against uncertainty and cost‑effectiveness within formal technology‑assessment frameworks.
• Private‑clinic infrastructure: Dedicated telehealth and specialty clinics have streamlined patient onboarding, pharmacy links and import supply chains, enabling higher throughput per prescriber and making cannabis-based products a core business line rather than an occasional add‑on.
• Training and familiarity: Few specialists have formal training or sustained experience with cannabis-based products, so those who do naturally accrue disproportionate caseloads and become default referral destinations for GPs unwilling or unable to prescribe.

Public‑health and regulatory risks from concentration

Concentration on this scale is not merely a market curiosity; it has direct implications for patient safety, equity and institutional accountability.

• Variation in practice: Oversized influence of a small cohort can entrench idiosyncratic dosing, product choice and indications, with limited peer counterbalance or multi‑disciplinary challenge.
• Safety signal detection: Pharmacovigilance relies on broad participation; narrow prescriber bases can slow detection of rare adverse events across different products and potencies, particularly for high‑THC formulations.
• Conflict‑of‑interest exposure: Where clinics also dispense or have commercial ties to importers or cultivators, audit trails must be especially robust and transparently documented to preserve public confidence.
• System resilience: If a few prescribers stop practicing, thousands of patients could lose continuity of care for controlled medicines, forcing local systems to improvise handovers at short notice.
• Equity: Private‑only pathways put lower‑income patients at a disadvantage, raising concerns of a two‑tier system for symptom control in pain, neurology and palliative contexts.

What effective oversight should look like

Existing frameworks already assign clear roles across agencies, anchored in the UK’s Misuse of Drugs Act and associated controlled‑drugs regulations. The challenge is applying them coherently to a fast‑growing, privately delivered market in which data and accountability sit across public and commercial actors.

Policy measures that match the moment

The spike in private activity, coupled with a narrow prescriber base, strengthens the case for light‑touch but clear national guardrails rather than piecemeal local responses.

• Structured accreditation for initiators of cannabis-based products, refreshed on a fixed cycle, focused on dosing, drug-drug interactions, and impairment risk.
• National outlier review thresholds for controlled drugs that automatically trigger peer review when individual prescribers exceed defined volume or potency benchmarks.
• Mandatory, privacy‑protective reporting of private prescriptions into a central dataset with product‑level detail to support surveillance, service planning and independent research.
• Potency‑step protocols and maximum initial daily THC thresholds for new starts, with documented justification for escalation.
• Linked outcomes registry tracking pain scores, function, sleep, and adverse events at defined intervals to strengthen the evidence base and inform future guideline updates.
• Procurement separation and disclosure rules where clinics both prescribe and dispense, to reduce perceived or real conflicts.

Equity, access and workforce capacity

The concentration of prescribing intersects with affordability, geography and workforce constraints. Out‑of‑pocket private fees can exclude patients with chronic pain, spasticity or refractory nausea who might otherwise benefit under specialist supervision. At the same time, the NHS workforce has limited bandwidth to absorb complex shared‑care arrangements without clearer guidance, commissioning support and time in job plans.

The governance path forward

None of the system fixes above require new primary legislation. Existing controlled‑drug regulations, the regulator’s oversight toolkit, and clinical guidance on cannabis-based products already outline safe‑use principles – from specialist initiation to careful titration and monitoring. The immediate task for regulators, commissioners and professional leaders is consistent application to a market where prescribing volume has grown quickly and clustered among a small number of doctors.

For readers seeking the technical underpinnings, the national regulator’s controlled‑drugs update summarises trends and recommendations for safer management, while a concise summary of clinical guidance on cannabis‑based medicinal products sets the expectations for specialist initiation and monitoring in both NHS and independent settings. Taken together, they provide a roadmap to reduce unwarranted variation, shore up accountability and safeguard patients as access evolves.